Jeff Hall

A fully convolutional data description (FCDD) model for identifying anomalies on breast MRI demonstrated an 84 percent AUC for detection tasks in a balanced cohort with a 20 percent malignancy prevalence and a 72 percent AUC for detection tasks in an imbalanced group with a 1.85 percent cancer prevalence.

A cloud-based and AI-native radiology operating system, MosaicOS reportedly enables the combination of diagnostic AI tools and workflow enhancements into one scalable platform.

The updated capabilities of SwiftMR include personalized scan settings within the software, artifact reduction and cloud integration.

Emerging research revealed significantly enhanced sensitivity for prostate cancer detection with adjunctive and stand-alone use of AI.

For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.

For patients who had coronary CTA for acute chest pain, emerging research found no significant association between plaque burden grades with CAD-RADS 2.0 and cardiac events.

EchoGo Amyloidosis, an echocardiography-based AI screening software, demonstrated a 93 percent AUROC for cardiac amyloidosis detection in a new multicenter study.

For pediatric patients with congenital heart disease, new research showed that cardiac PCCT yielded comparable signal-to-noise and contrast-to-noise ratios to energy-integrating detector CT at over a 43 percent lower dose length product.

Currently in a phase I trial for solid prostate cancer tumors, the deoxycytidine kinase inhibitor TRE-515 garnered the fast track designation for possible combination use with Pluvicto in treating mCRPC.

In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.

For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.

Findings from the TRAILBLAZER-ALZ 6 study revealed a 41 percent reduction of the ARIA-E side effect at 24 weeks with the new dosing schedule for the anti-amyloid treatment donanemab-azbt.

The HCPCS level II code A9616 goes into effect on October 1 for the PSMA PET preparation kit, which received FDA approval in March.

For patients with amyloid β (Aβ)-positive findings on positron emission tomography, higher educational attainment was associated with accelerated accumulation and spread of tau, according to new research.

While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.

The use of SIR-Spheres achieved a 98.5 percent overall response rate in the treatment of hepatocellular carcinoma in a recent prospective multicenter trial.

In a recent interview at the SNMMI conference, Ryota Satoh, Ph.D., discussed new positron emission tomography (PET research examining the role of neuroinflammation in differentiating between progressive apraxia of speech (PAOS) and Parkinson-plus syndrome.

In external testing, a model combining radiological complete response on breast MRI, nodal status and Ki-67 proliferation index yielded an 88 percent AUC for predicting pathologic complete response to neoadjuvant chemoimmunotherapy for patients with triple-negative breast cancer, according to new research.

Preoperative use of contrast-enhanced cone-beam breast CT has over a 96 percent sensitivity for predicting nipple-areolar complex involvement in cases involving early-stage breast cancer, according to a new study.

The diagnostic tomographic 3D ultrasound imaging technology PIUR tUS inside will reportedly be available with select GE HealthCare Logiq systems.

The deep learning reconstruction software reportedly facilitates accelerated MRI scanning and significantly enhanced image sharpness.

For people with dilated cardiomyopathy and those with initially normal cardiac MRI, each 1 ug/m3 increase in one-year exposure to ambient fine particulate matter with 2.5-um > aerodynamic diameter was associated with significantly more diffuse myocardial fibrosis, according to a recent study.

The acoustic coupling fluid and sterile transfer kit reportedly removes acoustic artifacts that can occur with the use of standard irrigation fluids in ultrasound-guided neurosurgical interventions.

In a recent interview, Jean-Luc C. Urbain, M.D., Ph.D., the new president of the Society for Nuclear Medicine and Molecular Imaging, discussed current challenges in nuclear medicine and key goals, including improved access to nuclear medicine for people in underserved communities.

While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.

In a recent interview at the SNMMI conference Amir Iravani, M.D., discussed a new sub-analysis from the CONDOR study, which revealed consistently high positive predictive value for 18F-piflufolastat PSMA PET/CT in the detection of local prostate cancer recurrence.

Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.

In a recent interview at the SNMMI conference, Liza Lindenberg, M.D., discussed preliminary research findings that suggest the potential of the 18F-fluciclovine PET/CT for detection of multiple myeloma.

Artificial intelligence (AI) software had a 14 percent false negative rate in a new study involving over 1,082 women with invasive breast cancer.

For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.